Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by gojotv!on Nov 30, 2021 8:26pm
419 Views
Post# 34183015

Time for some napkin math again...

Time for some napkin math again...So, CTV News at Six is watched by 1.6 million viewers...
Let's say two million when you add in late-night viewership of re-run stories.
If a mere 2% were interested in the story, (conservative estimate) that's 20,000 people looking up SZLS.
If one out of ten of those decide they want and can afford Aristotle, That's 2,000 people.
And if a mere half of them get the test, that's 1,000 people x $1000 profit.
That's a million right there. Effortless.
And this was just a first mass PR volley.
More advertising should heighten awareness more. 
And physicians are an easy group to target with publicity. Cheaper to reach them than the general market...
Things are shaping up the way I like.


<< Previous
Bullboard Posts
Next >>